DEF 14A: Vaxart Seeks Stockholder Approval for Share Increase and Equity Plan Amendments

Vaxart is asking stockholders to approve an increase in authorized shares and amendments to its equity incentive plans at the upcoming annual meeting.

Summary

• Vaxart is holding its 2024 Annual Meeting of Stockholders on June 11, 2024, via live webcast.
• Stockholders will vote on several proposals, including the election of six directors, an amendment to the Restated Certificate of Incorporation to increase the authorized number of common stock shares to 350,000,000, and amendments to the 2019 Equity Incentive Plan and the 2022 Employee Stock Purchase Plan.
• The proposed amendment to the 2019 Equity Incentive Plan would increase the number of shares reserved for issuance by 15,000,000 to a total of 43,900,000 shares.
• The proposed amendment to the 2022 Employee Stock Purchase Plan would increase the number of shares reserved for issuance by 1,800,000 to a total of 3,600,000 shares.
• Stockholders will also vote to ratify the selection of WithumSmith+Brown, PC as the independent registered public accounting firm for the year ending December 31, 2024, and to approve, on a non-binding, advisory basis, the compensation of the company's named executive officers.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The proposals are aimed at providing the company with greater flexibility and resources, which is viewed positively. However, the potential for dilution and the past bankruptcy of a company led by the new CEO temper the overall sentiment.

Positives

• Increasing the authorized shares provides greater flexibility for future corporate needs, including raising capital and strategic transactions.
• Amending the equity incentive plans helps attract and retain key employees, consultants, advisors, executive officers, and directors.
• The 2019 Equity Incentive Plan includes provisions designed to protect stockholders' interests and reflect corporate governance best practices.
• The 2022 Employee Stock Purchase Plan improves opportunities for employees to benefit from increases in the company's stock value.

Negatives

• Increasing the authorized shares could lead to further dilution of the outstanding shares of common stock.
• Zosano Pharma Corporation, where Steven Lo served as CEO, filed for bankruptcy in 2022.

Risks

• The company's future success depends on its ability to attract, motivate, and retain high-caliber employees, consultants, and directors.
• Stock price volatility could impact the effectiveness of equity compensation.
• Failure to obtain stockholder approval for the proposed amendments could limit the company's flexibility in attracting and retaining talent and pursuing strategic opportunities.

Future Outlook

The board of directors believes it is in the company's best interest to increase the number of authorized shares of common stock to give it greater flexibility in considering and planning for future corporate needs, including raising additional capital, making long-term equity incentive awards, attracting and retaining key employees, considering potential strategic transactions, funding operations, and other general corporate purposes.

Management Comments

• The board of directors believes that the decision as to whether the positions of Chair and Chief Executive Officer should be combined or separated should be based upon the particular circumstances facing the Company.
• The board of directors believes that additional authorized shares of common stock will enable us to take timely advantage of market conditions and favorable financing and acquisition opportunities that may become available to us without the delay and expense associated with convening a special meeting of our stockholders.

Industry Context

Vaxart operates in the competitive biotechnology industry, focused on developing oral recombinant vaccines. The company's compensation peer group consists of other US-based, publicly traded, early-stage pre-commercial biopharma companies.

Comparison to Industry Standards

• The company benchmarks its executive and director compensation against a peer group of 18 public life science companies with similar characteristics, including market capitalization and headcount.
• The company generally attempts to structure base salary and total cash compensation for named executive officers at approximately the 25th to 50th percentile of the market data and LTI opportunities at approximately the 50th to 75th percentile of the market data.

Management Changes

Corporate Governance

Related Party Transactions

• The company has entered into indemnity agreements with its executive officers and directors.
• The company has entered into letter agreements, employment agreements and change in control arrangements with its executive officers.
• The company has granted stock options to its executive officers and members of its board of directors.

Stakeholder Impact

• Approval of the proposals would provide the company with greater flexibility and resources, which could benefit shareholders.
• Amending the equity incentive plans and employee stock purchase plan could improve employee morale and retention.
• The selection of an independent registered public accounting firm helps ensure the integrity of the company's financial reporting.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on June 11, 2024.
• The company will file the Certificate of Amendment with the Secretary of State of the State of Delaware if Proposal No. 2 is approved.
• The company intends to file a Registration Statement on Form S-8 relating to the issuance of additional shares under the 2019 Plan and the 2022 ESPP with the SEC after approval of the amended and restated plans by stockholders.

Key Dates

Keywords

proxy statement, annual meeting, stockholders, equity incentive plan, employee stock purchase plan, authorized shares, directors, executive compensation, WithumSmith+Brown